相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)
Emanuele Angelucci et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes
Michel Delforge et al.
LEUKEMIA RESEARCH (2014)
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes
Norbert Gattermann et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging
Emanuela Messa et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis
E. Messa et al.
ACTA HAEMATOLOGICA (2008)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
分享论文
